Actos Bladder Cancer Link Alleged in Lawsuit

If the diabetes does not kill you, the bladder cancer might. That’s the gist of a lawsuit, filed April 25 in the Louisiana Western District Court, in which plaintiff Donald Shingleton alleges he suffers from bladder cancer after taking Actos for se

veral years.

Actos is a drug used to control type 2 diabetes. It has been a blockbuster for its maker, Japan-based Takeda which last year logged $4.5 billion in Actos sales.

Diabetes is an ever more common disease in the United States. The American Diabetes Association estimates that nearly 26 million of us – almost 10 percent of the population – suffers from diabetes, a disease characterized by the body’s inability to manufacture or to efficiently use insulin. It is linked to cardiovascular disease, kidney failure and blindness. [Continue reading…]

Actos Bladder Cancer Risk Shown in May 31, 2012 Study

Actos bladder cancer risks shown in May 31, 2012 study, establishes Actos bladder cancer risk.

Actos, the trade name for the diabetes drug Pioglitazone, is associated with an increased risk of bladder cancer, finds a study pub

lished on today.

The results show that more than two years daily exposure to pioglitazone doubles the risk of Actos bladder cancer.

Actos bladder cancer risks were evaluated in a new study reported in on May 31, 2012. The study confirms previous studies

showing an Actos bladder cancer risk. According to an excerpt from the article, the Actos bladder cancer risk is clearly established:

Use of the anti-diabetic agent pioglitazone (Actos) is associated with an increased risk of bladder cancer, a nested case-control study confirmed.

Patients with type 2 diabetes who were ever treated with pioglitazone [Actos] had an 83% higher risk for bladder cancer (adjusted rate ratio 1.83, 95% CI 1.10 to 3.05) than those who had never used the thiazolidinedione, according to Laurent Azoulay, PhD, of McGill University in Montreal, and colleagues.

This was a drug-specific effect, because patients taking rosiglitazone (Avandia) did not have an elevated risk (RR 1.14, 95% CI 0.78 to 1.68), the

researchers reported online in


The results of this analysis differed from those of a study being presented this week at the annual meeting of the American Society of Clinical Oncology, which suggested that the bladder cancer risk was a class effect for glitazones.

Other previous efforts to ascertain if pioglitazone [Actos] is associated with bladder cancer have had conflicting results, but the FDA and the Canadian health authorities have added a warning of that risk to the drug’s labeling, and some European countries have restricted its use.

(Emphasis added)

In other articles published today about the study, ScienceCodex reported that the new study shows that 2 years of treatment with Actos doubles the risk of bladder cancer.

(Emphasis added).

Actos Bladder Cancer Resources May 31, 2012: